Literature DB >> 5733780

[A further contribution to the knowledge of the Hallervorden-Spatz disease].

F Gallyas, S Környey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5733780     DOI: 10.1007/bf00341968

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


× No keyword cloud information.
  7 in total

1.  [CONTRIBUTION TO LATE INFANTILE HALLERVORDEN-SPATZ DISEASE].

Authors:  F SEITELBERGER; E GOOTZ; H GROSS
Journal:  Acta Neuropathol       Date:  1963-09-02       Impact factor: 17.088

2.  NEUROAXONAL DYSTROPHY IN MUCOVISCIDOSIS.

Authors:  J H SUNG
Journal:  J Neuropathol Exp Neurol       Date:  1964-10       Impact factor: 3.685

3.  [METABOLIC DISORDERS IN HALLERVORDEN-SPATZ DISEASE].

Authors:  S KOERNYEY
Journal:  Arch Psychiatr Nervenkr       Date:  1964-03-16

4.  AN ELECTRON MICROSCOPIC STUDY OF DYSTROPHIC AXONS IN THE GRACILE AND CUNEATE NUCLEI OF VITAMIN E-DEFICIENT RATS.

Authors:  P LAMPERT; J M BLUMBERG; A PENTSCHEW
Journal:  J Neuropathol Exp Neurol       Date:  1964-01       Impact factor: 3.685

5.  Hallervorden-Spatz disease. Late infantile and adult types, report of two cases.

Authors:  B Rozdilsky; J N Cumings; A F Huston
Journal:  Acta Neuropathol       Date:  1968-01-02       Impact factor: 17.088

6.  A study of iron metabolism in neuropsychiatric patients. Hallervorden-Spatz disease.

Authors:  J Szanto; F Gallyas
Journal:  Arch Neurol       Date:  1966-04

7.  Infantile neuroaxonal dystrophy. (Seitelberger's disease). Report of an autopsy case.

Authors:  Y Takei
Journal:  Acta Neuropathol       Date:  1965-10-04       Impact factor: 17.088

  7 in total
  2 in total

Review 1.  Iron chelation and multiple sclerosis.

Authors:  Kelsey J Weigel; Sharon G Lynch; Steven M LeVine
Journal:  ASN Neuro       Date:  2014-01-30       Impact factor: 4.146

Review 2.  Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.

Authors:  Vassilena Iankova; Ivan Karin; Thomas Klopstock; Susanne A Schneider
Journal:  Front Neurol       Date:  2021-04-15       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.